Johnson & Johnson Invests in Orasis' QLOSI™ eyedrops

When Johnson & Johnson learned of the groundbreaking work from Orasis Pharmaceuticals, an emerging ophthalmic pharmaceuticals company, they knew it has the potential to be an excellent complement to their existing expertise in solutions to treat presbyopia, or loss of near vision, in adults. On September 19, 2024, J&J closed a transaction as the co-lead investor of Series D funding in Orasis Pharmaceuticals, creators of the QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, prescription eye drops, for presbyopes seeking a break from readers.

Read more about this round from J&J.